MDA MB 361(mammary carcinoma cell line) |
Cytotoxic assay |
|
|
|
The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase), IC50=17 nM |
10395490 |
P388 leukemia cell line |
Cytotoxic assay |
|
|
|
Compound was evaluated for cytotoxicity against P388 leukemia cell line, IC50=3 nM |
10479297 |
Dx5 w/PSC cell lines |
Growth inhibition assay |
|
|
|
The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay, IC50=14 nM |
10698449 |
MES-SA uterine tumor cell lines |
Growth inhibition assay |
|
|
|
The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay, IC50=0.021 μM |
10698449 |
Dx5 cell lines |
Growth inhibition assay |
|
|
|
The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay, ic50=2 μM |
10698449 |
human epidermoid carcinoma cell line KB-3-1 |
Cytotoxic assay |
|
|
|
In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1, IC50=7 nM |
12443763 |
human uterine sarcoma cell line MES-SA |
Cytotoxic assay |
|
|
|
In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA, IC50=0.07 μM |
12443763 |
Jurkat T lymphocytes |
Cytotoxic assay |
|
|
|
Cytotoxicity against Jurkat T lymphocytes by MTT assay, IC50=0.0826 μM |
16366602 |
human HeLa3 cell line |
Cytotoxic assay |
|
|
|
Cytotoxicity against human HeLa3 cell line by MTT assay, IC50=2.96 μM |
16942037 |
NCI-H69 cell line |
Proliferation assay |
|
|
|
Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay, IC50=0.1 μM |
17286393 |
L1210 |
Function assay |
|
|
|
Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.3 μM. |
423181 |
L1210 |
Function assay |
|
|
|
Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 1 μM. |
423181 |
L1210 |
Function assay |
|
|
|
Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [3H]uridine incorporation, ED50 = 0.3 μM. |
490537 |
L1210 |
Function assay |
|
|
|
Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation, ED50 = 0.4 μM. |
490537 |
L1210 |
Function assay |
|
|
|
Inhibition of [3H]uridine incorporation into proliferating L1210 cells, ED50 = 0.33 μM. |
6716401 |
L1210 |
Function assay |
|
|
|
Inhibition of [3H]thymidine incorporation into proliferating L1210 cells, ED50 = 0.66 μM. |
6716401 |
L1210 |
Function assay |
|
|
|
Dose required to inhibit the RNA synthesis in leukemia L1210 cells, ED50 = 0.3 μM. |
7252976 |
L1210 |
Function assay |
|
|
|
Dose required to inhibit the DNA synthesis in leukemia L1210 cells, ED50 = 1 μM. |
7252976 |
MCF7 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 0.22 μM. |
17190447 |
MDA-MB-231 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 0.25 μM. |
17190447 |
HeLa |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.32 μM. |
17190447 |
PC-3 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human PC-3 cells after 48 hrs by MTT assay, IC50 = 0.44 μM. |
17190447 |
Yoshida sarcoma tumor cells |
Function assay |
|
|
|
Concentration inhibiting [3H]TdR incorporation in Yoshida sarcoma tumor cells in vitro in rats, IC50 = 0.02 μM. |
1322986 |
HL60 |
Apoptosis assay |
|
|
|
In vitro concentration required to induce apoptosis in HL60 cells, AC50 = 0.04 μM. |
12877593 |
HL60R |
Apoptosis assay |
|
|
|
In vitro concentration required to induce apoptosis in HL60R cells, AC50 = 10 μM. |
12877593 |
HL60 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method, AC50 = 0.1 μM. |
18339455 |
HL60 |
Apoptosis assay |
|
|
|
Induction of apoptosis in multidrug resistant human HL60 cells after 48 hrs, AC50 = 38 μM. |
18339455 |
HTB-81 |
Cytotoxicity assay |
|
|
|
Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in human prostate cancer HTB-81 cells using MTS assay, EC50 = 0.058 μM. |
11020285 |
B16 |
Cytotoxicity assay |
|
|
|
Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay, EC50 = 0.16 μM. |
11020285 |
fibroblast (NHF) cells |
Cytotoxicity assay |
|
|
|
Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in normal human fibroblast (NHF) cells using MTS assay, EC50 = 0.22 μM. |
11020285 |
L1210 |
Function assay |
|
3 hrs |
|
Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.3 μM. |
176359 |
L1210 |
Function assay |
|
3 hrs |
|
Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.3 μM. |
176359 |
L1210 |
Function assay |
|
|
|
Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.33 μM. |
423182 |
L1210 |
Function assay |
|
|
|
Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 0.66 μM. |
423182 |
L1210 |
Function assay |
|
|
|
Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.33 μM. |
490536 |
L1210 |
Function assay |
|
|
|
Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 0.66 μM. |
490536 |
L1210 |
Function assay |
|
|
|
Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.23 μM. |
690999 |
L1210 |
Function assay |
|
|
|
Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 0.48 μM. |
690999 |
L1210 |
Function assay |
|
|
|
Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the RNA (inhibition of synthesis in leukemia L1210 cells), ED50 = 0.33 μM. |
3761325 |
L1210 |
Function assay |
|
|
|
Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the DNA (inhibition of synthesis in leukemia L1210 cells), ED50 = 0.66 μM. |
3761325 |
L1210 |
Function assay |
|
|
|
Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells, ED50 = 0.33 μM. |
7086816 |
L1210 |
Function assay |
|
|
|
Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells, ED50 = 0.66 μM. |
7086816 |
NCI60 |
Growth inhibition assay |
|
|
|
Growth inhibition of human NCI60 cells, GI50 = 0.044 μM. |
19944612 |
MDA-MB-231 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, GI50 = 0.02 μM. |
19968258 |
HT-29 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay, GI50 = 0.07 μM. |
19968258 |
A549 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, GI50 = 0.08 μM. |
19968258 |
K562 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human K562 cells after 72 hrs by XTT assay, GI50 = 0.0074 μM. |
20591678 |
NCI-H460 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay, GI50 = 0.38 μM. |
20591678 |
SF268 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human SF268 cells after 72 hrs by XTT assay, GI50 = 0.6 μM. |
20591678 |
MCF7 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay, GI50 = 0.86 μM. |
20591678 |
Detroit 551 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay, GI50 = 1.77 μM. |
20591678 |
HL60 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis, GI50 = 0.1 μM. |
25874335 |
HL60R |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human HL60R cells expressing p-glycoprotein assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis, GI50 = 38 μM. |
25874335 |
P388 |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay, IC50 = 0.028 μM. |
2778449 |
HT-29 |
Antiproliferative assay |
|
96 hrs |
|
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay, IC50 = 0.133 μM. |
2778449 |
HeLa |
Function assay |
|
|
|
TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells, IC50 = 8 μM. |
8621644 |
breast carcinoma line cells |
Function assay |
|
|
|
compound was tested in vitro for inhibition activity against a sensitive human breast carcinoma line cells, IC50 = 0.06 μM. |
9258351 |
breast carcinoma line cells |
Function assay |
|
|
|
compound was tested in vitro for inhibition activity against doxorubicin resistant counterpart of human breast carcinoma line cells, IC50 = 2 μM. |
9258351 |
MCF-7 |
Function assay |
|
|
|
Compound was tested for its toxicity against human breast cancer cells(MCF-7), IC50 = 0.06 μM. |
9548820 |
MCF-7/ADR |
Function assay |
|
|
|
Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR), IC50 = 2 μM. |
9548820 |
L1210 |
Function assay |
|
|
|
Inhibitory activity was measured against murine L1210 leukemia cells, IC50 = 0.03 μM. |
9733483 |
HL60 |
Function assay |
|
|
|
In vitro inhibitory concentration against proliferation of HL60 cells, IC50 = 0.005 μM. |
12877593 |
HL60R |
Function assay |
|
|
|
In vitro inhibitory concentration against proliferation of HL60R cells along with 5 (uM) verapamil, IC50 = 0.04 μM. |
12877593 |
HL60R |
Function assay |
|
|
|
In vitro inhibitory concentration against proliferation of HL60R cells, IC50 = 1.5 μM. |
12877593 |
K562 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against K562 cells by MTS, IC50 = 0.015 μM. |
16451059 |
P388 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against P388 cells by ELISA, IC50 = 0.025 μM. |
17154505 |
P388 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA, IC50 = 0.04 μM. |
17154505 |
MDA435/LCC6 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against MDA435/LCC6 cells by ELISA, IC50 = 0.079 μM. |
17154505 |
P388 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA, IC50 = 0.106 μM. |
17154505 |
MDA435/LCC6 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA, IC50 = 0.129 μM. |
17154505 |
MDA435/LCC6 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA, IC50 = 0.977 μM. |
17154505 |
P388 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against adriamycin resistant P388 cells by ELISA, IC50 = 2.111 μM. |
17154505 |
A2780 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay, IC50 = 0.11749 μM. |
17890094 |
A2780/ADR |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human A2780/ADR cells after 72 hrs by MTT assay, IC50 = 18.6209 μM. |
17890094 |
NIH/3T3 |
Cytotoxicity assay |
|
72 hrs |
|
Intrinsic cytotoxicity against wild type mouse NIH/3T3 cells after 72 hrs by MTT assay, IC50 = 0.044 μM. |
18954040 |
NIH/3T3 |
Cytotoxicity assay |
|
72 hrs |
|
Intrinsic cytotoxicity against mouse NIH/3T3 cells overexpressing MDR1 after 72 hrs by MTT assay, IC50 = 1.01 μM. |
18954040 |
KB |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human KB cells after 48 hrs by MTT assay, IC50 = 0.64 μM. |
20363142 |
KB-C2 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human multidrug-resistant KB-C2 cells after 48 hrs by MTT assay, IC50 = 16.2 μM. |
20363142 |
HT-29 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay, IC50 = 0.4 μM. |
21094049 |
HepG2 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay, IC50 = 0.7 μM. |
21094049 |
NIH/3T3 |
Cytotoxicity assay |
|
3 days |
|
Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay, IC50 = 1.8 μM. |
21094049 |
Vero |
Cytotoxicity assay |
|
3 days |
|
Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay, IC50 = 2.5 μM. |
21094049 |
MCF7 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay, IC50 = 5.5 μM. |
21094049 |
CRL7761 |
Cytotoxicity assay |
|
3 days |
|
Cytotoxicity against human CRL7761 cells after 3 days by MTS assay, IC50 = 10.5 μM. |
21094049 |
NCI-H460 |
Anticancer assay |
|
|
|
Anticancer activity against human NCI-H460 cells, IC50 = 0.38 μM. |
21599000 |
SF268 |
Anticancer assay |
|
|
|
Anticancer activity against human SF268 cells, IC50 = 0.6 μM. |
21599000 |
MRC5 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against human MRC5 cells, IC50 = 0.88 μM. |
21599000 |
MCF7 |
Anticancer assay |
|
|
|
Anticancer activity against human MCF7 cells, IC50 = 5.03 μM. |
21599000 |
DU145 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay, IC50 = 0.09 μM. |
22260166 |
SKMES1 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay, IC50 = 0.17 μM. |
22260166 |
MCF7 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay, IC50 = 0.95 μM. |
22260166 |
LNCAP |
Cytostatic assay |
|
4 days |
|
Cytostatic activity against human LNCAP cells after 4 days by MTT assay, IC50 = 0.1 μM. |
22480495 |
HT-29 |
Cytostatic assay |
|
4 days |
|
Cytostatic activity against human HT-29 cells after 4 days by MTT assay, IC50 = 0.2 μM. |
22480495 |
MCF7 |
Cytostatic assay |
|
4 days |
|
Cytostatic activity against human MCF7 cells after 4 days by MTT assay, IC50 = 0.4 μM. |
22480495 |
HepG2 |
Function assay |
|
|
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells, IC50 = 2.99 μM. |
22586124 |
THP1 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay, IC50 = 26.9 μM. |
22939695 |
L5178Y |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay, IC50 = 0.3 μM. |
23199479 |
L5178Y |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay, IC50 = 0.73 μM. |
23199479 |
L5178Y |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay, IC50 = 2.32 μM. |
23199479 |
L5178Y |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay, IC50 = 7.73 μM. |
23199479 |
DA-3 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay, IC50 = 1.9 μM. |
24900668 |
SKOV3 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay, IC50 = 20.6 μM. |
24900668 |
ES2 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human ES2 cells after 24 hrs by XTT assay, IC50 = 25.5 μM. |
24900668 |
MCF7 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay, IC50 = 33.9 μM. |
24900668 |
MRC5 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against human MRC5 cells by XTT assay, IC50 = 0.078 μM. |
25467291 |
A549 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against human A549 cells by XTT assay, IC50 = 0.08 μM. |
25467291 |
MDA-MB-231 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against human MDA-MB-231 cells by XTT assay, IC50 = 0.091 μM. |
25467291 |
H1299 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against human H1299 cells by XTT assay, IC50 = 0.096 μM. |
25467291 |
MCF7 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against human MCF7 cells by XTT assay, IC50 = 0.65 μM. |
25467291 |
HEK293 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar Blue assay, IC50 = 12.55 μM. |
26937828 |
MCF7/ADR |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human MCF7/ADR cells after 48 hrs by SRB assay, IC50 = 7.12 μM. |
28246041 |
HCT16 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity in human HCT16 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 0.21 μM. |
28923382 |
A549 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 0.51 μM. |
28923382 |
MCF7 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 1.44 μM. |
28923382 |
RD |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 2.45 μM. |
28923382 |
HEK293 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 11.17 μM. |
28923382 |
CCRF-CEM |
Growth inhibition assay |
|
|
|
In vitro growth inhibitory activity against CCRF-CEM (human lymphoblastic leukemic) cells, ID50 = 0.04 μM. |
6951049 |
CCRF-CEM |
Function assay |
|
|
|
Inhibitory activity against CCRF-CEM(human leukemic lymphoblastic) cells in culture, ID50 = 0.04 μM. |
7057426 |
Sf9 |
Function assay |
|
|
|
TP_TRANSPORTER: ATP hydrolysis in membrane vesicle from BCRP-expressing Sf9 cells, Kact = 2.5 μM. |
11437380 |
GLC4/ADR |
Function assay |
|
|
|
TP_TRANSPORTER: inhibition of DNP-SG uptake in membrane vesicles from GLC4/ADR cells, Ki = 0.95 μM. |
9188796 |
SR3A |
Function assay |
|
|
|
TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicles from SR3A cells, Ki = 0.07 μM. |
9647783 |
Caco-2 |
Function assay |
|
|
|
TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells, Ki = 2.5 μM. |
11405287 |
MDCK |
Function assay |
|
|
|
TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) in MRP2-expressing MDCK cells, Ki = 49.4 μM. |
12134946 |
GLC4/ADR |
Function assay |
|
|
|
TP_TRANSPORTER: efflux in GLC4/ADR cells, Km = 1.4 μM. |
7945406 |
BTI-TN5B1-4 |
Function assay |
|
|
|
TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells, Km = 1.74 μM. |
11785684 |
A549 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, LC50 = 0.35 μM. |
19968258 |
MDA-MB-231 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, LC50 = 0.86 μM. |
19968258 |
CEM |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against CEM cells after 72 hrs, TCS50 = 0.062 μM. |
17608396 |
MCF7 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against MCF7 cells after 72 hrs, TCS50 = 0.14 μM. |
17608396 |
K562 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against K562 cells after 72 hrs, TCS50 = 0.23 μM. |
17608396 |
HOS |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against HOS cells after 72 hrs, TCS50 = 0.33 μM. |
17608396 |
G361 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human G361 cells after 72 hrs, TCS50 = 0.67 μM. |
17608396 |
HeLa |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against HeLa cells after 72 hrs, TCS50 = 0.67 μM. |
17608396 |
MDA-MB-231 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, TGI = 0.12 μM. |
19968258 |
A549 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, TGI = 0.17 μM. |
19968258 |
HT-29 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay, TGI = 0.33 μM. |
19968258 |
K562 |
Function assay |
|
|
|
Increase in the level of drug uptake in Dox-resistant K562 cells in presence of cyclosporine over its absence |
16451059 |
K562 |
Function assay |
|
|
|
Increase in the level of drug efflux in Dox-resistant K562 cells in presence of cyclosporine over its absence |
16451059 |
KB |
Apoptosis assay |
1 uM |
24 hrs |
|
Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs |
18680275 |
DU145 |
Function assay |
90 nM |
72 hrs |
|
Inhibition of topoisomerase 2 in human DU145 cells assessed as stabilization of enzyme-DNA cleavage complex at 90 nM after 72 hrs by immunoblot analysis |
22260166 |
DU145 |
Function assay |
90 nM |
30 mins |
|
Inhibition of topoisomerase 2 in human DU145 cells assessed as stabilization of enzyme-DNA cleavage complex at 90 nM after 30 mins by immunoblot analysis |
22260166 |
DU145 |
Function assay |
500 nM |
4 hrs |
|
Inhibition of HDAC6-mediated tubulin acetylation in human DU145 cells at 500 nM after 4 hrs by Western blot analysis |
22260166 |
DU145 |
Function assay |
0.1 to 0.5 uM |
24 hrs |
|
Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis |
22260166 |
DA-3 |
Cytotoxicity assay |
20 uM |
60 mins |
|
Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM after 60 mins by XTT assay |
24900668 |
TC32 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells |
29435139 |
DAOY |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells |
29435139 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
BT-37 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
U-2 OS |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells |
29435139 |
Saos-2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells |
29435139 |
SK-N-SH |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells |
29435139 |
NB1643 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells |
29435139 |
BT-12 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells |
29435139 |
Rh18 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
RD |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells |
29435139 |
fibroblast cells |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells |
29435139 |
Rh41 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells |
29435139 |
P388 |
Antitumor assay |
0.25 to 10 mg/kg |
|
|
Antitumor activity against mouse P388 cells allografted in mouse assessed as tumor growth inhibition at 0.25 to 10 mg/kg |
1255661 |